



Pharmaceuticals – Pipeline Overview¹ (as of February 11, 2026)

Phase I
VVD KEAP1 Act (VVD-130037 aka <i>NRF2 Inh</i> , BAY 3605349)  ●
225Ac-Pelgifatamab (BAY 3546828)  ●
225Ac-PSMA-Trillium (BAY 3563254)  ●
SOS1 Inhibitor (BAY 3498264)  ●
PRMT5 Inhibitor (BAY 3713372)  ●
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)  ●
225Ac-GPC3 (BAY 3547926)  ●
VVD WRN Inhibitor (VVD-214)  ●
KRAS G12D Inhibitor (BAY 3771249)  ●
Dual FIIa/Xa Inhibitor (BAY 3389934)  ●
GIRK4 Inhibitor (BAY 3670549) ●
BAY 3620122  ●
Multiple System Atrophy AAV Gene Therapy (AB-1005 aka <i>AAV2-GDNF-MSA</i>)  ●
Pompe Disease AAV Gene Therapy (AB-1009 aka <i>PROGRESS-GT LOPD</i>)  ●
LGMD2I/R9 AAV Gene Therapy (AB-1003 aka <i>LION-101</i>)  ●
GPR84 Antagonist (BAY 3178275)  ●
BAY 2701250  ●
Primary Photoreceptor Diseases Cell Therapy (BRT-OpCT-001)  ●
AT-05 SPECT Tracer  ●

Phase II
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)  ○
// Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)
Congestive Heart Failure AAV Gene Therapy (AB-1002)  ●
// Congestive Heart Failure (GenePHIT)
Inclacibart (anti-a2AP) (BAY 3018250)  ●
// Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)
Nurandociguat (sGC Activator Oral) (BAY 3283142)  ●
// Chronic Kidney Disease (ALPINE-1)
SEMA 3a Inhibitor (BAY 3401016)  ●
// Alport Syndrome (ASSESS)
Parkinson's Disease AAV Gene Therapy (AB-1005)  ●
// Parkinson's Disease (REGENERATE-PD)

Phase III
Darolutamide (AR Inhibitor)  ○
// Adjuvant Prostate Cancer (DASL-HiCaP) // Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)
Sevabertinib (HER2/mEGFR Inhibitor)  ○
// Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)
Finerenone (MR Antagonist)  ○
// Non-diabetic Chronic Kidney Disease (FIND-CKD) // Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)
Vericiguat (sGC Stimulator)  ○
// Heart Failure (HFrEF) (VICTOR ²)
Asundexian (FXIa Inhibitor)  ●
// 2 ^o Stroke Prevention (OCEANIC-STROKE)
Bemdaneprocel (Cell Therapy)  ●
// Parkinson's Disease (exPDite-2)
Mirena (Levonorgestrel-releasing Intrauterine System)  ○
// Endometrial Hyperplasia (SUNFLOWER)
124I-Evuzamitide (PET Tracer)  ●
// Diagnosis of Cardiac Amyloidosis (REVEAL)

Submissions
Sevabertinib (HER2/mEGFR Inhibitor)  ●
// CN, JP: HER2-mut NSCLC 2L
Finerenone (MR Antagonist)  ○
// EU, CN: Heart Failure (HFmr/pEF)
Aflibercept 8mg (VEGF-Inhibitor)  ○
// JP, CN: Retinal Vein Occlusion
Gadoquatrane (High Relaxivity Contrast Agent)  ●
// US, EU, JP, CN: Magnetic Resonance Imaging

 Protein Therapy  Cell Therapy  Genetic Therapy  Radionuclide Therapy  Imaging Agent  Small Molecule

 Oncology
 Cardiovascular / Renal
 Neurology & Rare Diseases
 Immunology
 Others

 New Molecular Entity
 Indication Expansion

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Conducted by Merck & Co